

ASX Release

## Genepharm appoints Dr Roger Aston as independent non-executive Director

**4th February 2008, Melbourne:** Genepharm Australasia Limited (ASX:GAA) today announced the appointment of former managing director of Peptech Limited, Dr Roger Aston, as independent non-executive director of Genepharm. Dr Aston is one of the most experienced and commercially astute people in drug commercialisation in Australia.

Dr Aston brings more than 20 years experience in the pharmaceutical and healthcare industries in senior roles in the United Kingdom, Asia-Pacific and Australia. In conjunction with his new appointment, Roger continues to serve as an executive, non-executive director or chairman on a number of boards including Phase III drug development companies Clinuvel Limited and HalcyGen Pharmaceuticals Limited. Previously he founded and was CEO of pSiOncology Pte Limited, a joint venture based in Singapore between Singapore General Hospital, Biotech Research Ventures and pSiMedica Limited.

Beginning his career at major pharmaceutical company Wellcome plc (now Glaxo Smith Kline), Dr Aston's earlier positions include co-founder and director of the Australian arm of global nanotechnology company pSiVida Limited, CEO of pSiMedica Limited (UK), director of Cambridge Antibody Technology Limited (UK) and chairman of Cambridge Drug Discovery Limited (UK) (now BioFocus plc). Dr Aston also serves on the federal government's IRD board sub-committee for biologicals.

Genepharm also announces that George Rogers (Kip) Harding is resigning from his position as a director of Genepharm. Kip continues in his executive role as Group General Manager Finance & Investment with the company.

Mr Tom O'Brien, chairman of Genepharm says: "We record our thanks to Kip for his services to the board. We continue to benefit from his initiative and ongoing work in his continuing senior role with Genepharm."

"The board also welcomes Dr Roger Aston to Genepharm. His depth of experience in regulatory matters, commercial drug development and sales strengthens our Board."

Dr Aston has a Bachelor of Science (Honours) degree and PhD from the University of Manchester, United Kingdom.

### Enquiries:

**Tom O'Brien**  
**Genepharm Australasia**  
**03 9699 2300**

**Rudi Michelson**  
**Monsoon Communications**  
**03 9620 3333**

### About Genepharm:

Genepharm Australasia (ASX:GAA) is a growth-oriented healthcare company with a particular focus on generics pharmaceuticals. Genepharm markets, sells and distributes a range of healthcare products ranging from blockbuster prescription drugs to cosmeceuticals. Genepharm services pharmacies, hospitals, medical centres and wholesalers. Genepharm is the second largest Australian generic pharmaceuticals company and the only dedicated generic pharmaceuticals company listed on the Australian Stock Exchange. The company was established in 2003 and listed on the ASX in 2004. For more info: [www.genepharm.com.au](http://www.genepharm.com.au).

For personal use only

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>GENEPHARM AUSTRALASIA LIMITED</b>
<b>ABN</b>	<b>52 107 340 367</b>

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>DR ROGER ASTON</b>
<b>Date of appointment</b>	<b>31 JANUARY 2008</b>

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Not Applicable

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3X**  
**Initial Director's Interest Notice**

---

**Part 2 – Director's relevant interests in securities of which the director is not the registered holder**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b>	<b>Number &amp; class of Securities</b>
Note: Provide details of the circumstances giving rise to the relevant interest.  Not Applicable	

**Part 3 – Director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not Applicable
<b>Nature of interest</b>	Not Applicable
<b>Name of registered holder (if issued securities)</b>	Not Applicable
<b>No. and class of securities to which interest relates</b>	Not Applicable

---

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>GENEPHARM AUSTRALASIA LIMITED</b>
	<b>52 107 340 367</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	<b>GEORGE ROGERS HARDING</b>
<b>Date of last notice</b>	<b>19 SEPTEMBER 2007</b>
<b>Date that director ceased to be director</b>	<b>31 JANUARY 2008</b>

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Not Applicable

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Z**  
**Final Director's Interest Notice**

---

**Part 2 – Director's relevant interests in securities of which the director is not the registered holder**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> Note: Provide details of the circumstances giving rise to the relevant interest	<b>Number &amp; class of securities</b>
Bora Bora Holdings Pty Ltd in which George Rogers Harding has a beneficial interest	3,040,000 Ordinary Shares

**Part 3 – Director's interests in contracts**

<b>Detail of contract</b>	Not Applicable
<b>Nature of interest</b>	Not Applicable
<b>Name of registered holder (if issued securities)</b>	Not Applicable
<b>No. and class of securities to which interest relates</b>	Not Applicable

---

+ See chapter 19 for defined terms.

For personal use only